New class of platelet blockers proves effective in phase III trial
Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in patients with known atherosclerosis, a hardening and narrowing of the arteries, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session. The Scientific Session, the premier cardiovascular medical meeting, brings cardiovascular professionals together to further advances in the field.
Each year, more than a million Americans suffer a heart attack. For those who survive, doctors routinely prescribe aspirin therapy to help prevent blood clot formation in the arteries that can lead to another heart attack. Other platelet blockers, such as clopidogrel, are often added for as long as a year but it is unclear whether adding any platelet blocker to aspirin beyond this timeframe is useful. Despite such therapies, survivors of heart attack have an almost 15 percent chance of having another atherosclerosis-related event that brings them to the hospital within a year.
Now, researchers led by the TIMI Study Group at Brigham & Women's Hospital in Boston, Mass. have shown, for the first time, that adding a new antiplatelet agent on top of standard therapy, including aspirin, is effective for long-term secondary prevention in stable patients with a prior heart attack. When used with aspirin and other standard antiplatelet therapy in a broad group of patients with previous heart attack, stroke or peripheral arterial disease, vorapaxar reduced the risk of cardiovascular death, heart attack or stroke by an additional 13 percent (9.3 vs. 10.5 percent at three years, p<0.001). This reduction in new cardiovascular events appeared greatest in patients with prior heart attack, among whom there was a 20 percent decline in these events (p<0.001).
Vorapaxar is the first of a new class of investigational Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonists. Unlike other antithrombotic drugs, vorapaxar blocks thrombin from stimulating platelets to stick together and create clots. Blood thinners, like coumadin, and other antiplatelets like aspirin or clopidogrel, do not directly target these same actions of thrombin.
"In the lab, we have seen very compelling science showing the importance of thrombin's action on platelets causing blood clots in arteries," said David A. Morrow, MD, MPH, senior investigator at the TIMI Study Group, director of the Samuel A. Levine Cardiac Unit at Brigham & Women's Hospital, and the study's lead investigator. "This is the first study to show definitively that blocking this pathway reduces the risk of suffering another cardiovascular event."
This randomized, double blind, placebo-controlled, multinational study followed 26,449 patients for more than two years while receiving standard antiplatelet therapy for established atherosclerosis, including previous heart attack (n=17,779), stroke (n=4,883), or atherosclerotic narrowing in the arteries of the legs (n=3,787). Participants were randomly assigned to either take the investigational platelet blocker (2.5 mg orally once daily) with standard therapy, or a placebo with standard therapy.
"It's exciting to find clearly that we can reduce the risk of a recurrent thrombotic event by adding another platelet inhibitor to aspirin over the long-term," Dr. Morrow said. "Adding this new class of antiplatelet therapy reduced the risk of new cardiac events in stable patients, especially among the subset of patients with a prior heart attack."
Dr. Morrow commented that if vorapaxar becomes available for clinical use, it does not appear suitable for everyone with atherosclerosis. "Of the groups we studied, the benefit was compelling to us only in patients with a prior heart attack," said Dr. Morrow. In addition, this new therapy was found to increase the risk of severe bleeding, including intracranial bleeding. The risk of intracranial bleeding was highest among patients who have suffered from previous strokes; vorapaxar would likely not be appropriate for stroke victims or patients at high risk of bleeding. Stroke patients who were enrolled in the study ended their participation early after advice by the study's data and safety monitoring board.
Patients who took vorapaxar had significantly more bleeding events (GUSTO moderate or severe bleeding at three years 4.2 percent with vorapaxar vs. 2.5 percent with placebo, p<0.001). Intracranial hemorrhage was higher with vorapaxar than placebo (1.0 vs. 0.5 percent, p<0.001) with lower overall rates in patients with no history of stroke (3 years: 0.6 percent with vorapaxar vs. 0.4 percent with placebo, p=0.049).
Dr. Morrow and his team look forward to learning more from this very rich dataset to identify the patients who may have the best balance of benefit vs. bleeding risk with this agent.
This study will be simultaneously published in New England Journal of Medicine and will be released online at the time of presentation.
Journal reference: New England Journal of Medicine
Provided by American College of Cardiology
- Merck blood thinner shows mixed results: study Mar 24, 2012 | not rated yet | 0
- Increased risk of heart attack or stroke for patients who are resistant to aspirin Jan 18, 2008 | not rated yet | 0
- Popular anti-platelet therapy reduces risk of cardiovascular events in men and women Nov 10, 2009 | not rated yet | 0
- Low-dose daily aspirin enough to help heart attack patients: study Mar 26, 2012 | not rated yet | 0
- New study suggests potent antiplatelet drug effective with low-dose aspirin Jun 27, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
1 hour ago So energy can only be converted... So when you squeeze the bulb on a blood pressure cuff, you are applying kinetic energy. Then the cuff fills with...
How does momentum, inertia and drag affect the motion of an object?
4 hours ago How does momentum and inertia affect changes in speed, when considering acceleration from thrust, or from decelleration from drag? Say, for a...
What is Time-Varying Voltage?
5 hours ago In circuits, we have no problem saying that the voltage difference between two point is [itex]\cos(\omega t)[/itex], but what does that actually...
Contextual Relationships Between Momentum, Energy, and Force.
7 hours ago *I apologize in advance for the length of this post, if you wish to reduce reading skip to paragraph 5. Or if you are super lazy, the final...
Barometric pressure and the math behind it. Very interesting, I think.
8 hours ago Hey guys, I was actually researching the life of Edmond Halley and discovered that he discovered the relationship between barometric pressure and the...
Doubts in electrostatics
14 hours ago I have a few questions pertaining to some concepts in electrostatics, I'd be grateful if someone would help me out. 1) When we place a positive...
- More from Physics Forums - Classical Physics
More news stories
(HealthDay)—Blood levels of free fatty acids are associated with insulin resistance during young adulthood and cardiovascular risk factors in later adulthood, according to a study published online May 13 ...
Cardiology 14 hours ago | not rated yet | 0 |
An experimental, inexpensive iPhone application transmitted diagnostic heart images faster and more reliably than emailing photo images, according to a research study presented at the American Heart Association's Quality ...
Cardiology 15 hours ago | not rated yet | 0
Extracorporeal membrane oxygenation (ECMO), a procedure traditionally used during cardiac surgeries and in the ICU that functions as an artificial replacement for a patient's heart and lungs, has also been used to resuscitate ...
Cardiology 17 hours ago | not rated yet | 0
Age has little to do with how patients should be treated after suffering a stroke, according to new research from the University of Georgia.
Cardiology 18 hours ago | not rated yet | 0 |
Depressed middle-aged women have almost double the risk of having a stroke, according to research published in Stroke: Journal of the American Heart Association.
Cardiology May 16, 2013 | not rated yet | 0
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
23 minutes ago | not rated yet | 0
For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests
Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...
1 hour ago | not rated yet | 0 |
The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...
12 hours ago | not rated yet | 0 |
(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...
13 hours ago | 3.7 / 5 (3) | 0 |
(AP)—A woman who lost both hands, her left leg and right foot after contracting a flesh-eating disease has been fitted with prosthetic hands.
1 hour ago | not rated yet | 0
In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...
10 hours ago | 3.7 / 5 (3) | 0 |